9960 (9960) Fair Value & Analysis

Healthcare · Market cap HK$1.0B

9 9960 9960 · HK

PriceHK$0.9800

Fair ValueHK$0.5900

Upside-39.8%

Quality42/100

Watch 9960 for free — get notified when fair value or trend changes. Watch for free

Evidence: Medium Range HK$0.4000 – HK$0.7800

Fair value as of: Jul 3, 2026

From 10 valuation models · updated today

Share price +2.6% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.9277 – HK$1.56 · fair‑value band HK$0.4000 – HK$0.7800 · the HK$0.9800 price screens above the HK$0.5900 fair value. As of Jul 3, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

9960 (9960) currently trades at HK$0.9800, while our model-based Fair Value estimate is HK$0.5900 — implying the stock looks roughly 39.8% overvalued today. We read business quality at 42/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

Over the trailing twelve months, 9960 generated revenue of HK$934M at a net margin of -6.3%. Revenue grew 4.9% year over year. It earns a return on equity of -2.0%. Net debt stands at HK$47.5M. Fundamentals as of Jul 3, 2026

Key figures & financial health

Revenue (TTM) HK$934M

Revenue growth (YoY) +4.9%

Net margin -6.3%

Return on equity -2.0%

Free cash flow HK$43.6M FY2025

Operating margin -21.6%

More key figures

EPS (TTM) HK$-0.0400

Dividend yield 9.1%

EPS growth (YoY) -72.7%

Net debt HK$47.5M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

9960 reported revenue of HK$934M in FY2025 versus HK$931M in FY2021, a compound +0.1%/yr. Reported net income was −HK$58.7M in FY2025.

Revenue +0.1%/yr

FY21 HK$931M

FY22 HK$1.4B

FY23 HK$967M

FY24 HK$928M

FY25 HK$934M

Net income

FY21 −HK$1.5B

FY22 HK$75.5M

FY23 HK$41.3M

FY24 −HK$54.6M

FY25 −HK$58.7M

Is 9960 fairly valued? → Check now

Similar stocks

6 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).

Stock	Price	Fair Value	vs Fair Value
Thermo Fisher Scientific Inc TMO	$482.04	$202.02	-58%
Danaher Corporation DHR	$183.63	$87.65	-52%
2359 2359	HK$152.80	HK$120.99	-21%
WuXi AppTec Co WUXAY	$18.59	$25.09	+35%
IDEXX Laboratories, Inc IDXX	$545.73	$255.77	-53%
Lonza Group LZAGY	$61.53	$15.70	-74%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 9960 (9960) undervalued?

As of Jul 3, 2026, our model estimates a fair value of HK$0.5900 versus a price of HK$0.9800 — about −40% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 9960?

Our model-based fair value for 9960 is HK$0.5900 (as of Jul 3, 2026), built from audited fundamentals. The current price is HK$0.9800.

What is the quality score of 9960?

9960 has a Quality Score of 42/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 9960 (9960)?

9960 reported trailing-twelve-month revenue of about HK$934M (latest available figure, as of Jul 3, 2026).

What is the net profit margin of 9960?

The net profit margin of 9960 is about -6.3%, meaning it is currently running at a net loss. Based on the latest reported figures.

Does 9960 pay a dividend?

9960 currently shows a dividend yield of about 9.14% relative to its recent price (as of Jul 3, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.